Stacey Esters

Stacey Esters serves as a key procurement professional within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate biomedical research for infectious, immunologic, and allergic disease threats. She manages acquisitions centered on high-containment laboratory research, diagnostic development, and medical countermeasure innovation, ensuring alignment with federal biosafety standards and public health preparedness goals. Her work directly enables NIAID’s strategic investments in advanced scientific infrastructure and rapid-response capabilities, primarily through research and development contracts requiring specialized technical expertise and compliance with federal biomedical procurement regulations. Esters maintains a focused contractor relationship with Quality Biological, Inc., a leading provider of biological reference materials and biosafety-critical reagents, and GENOMIC LABS LTD, a specialist in genomic sequencing and bioinformatics services. These partnerships reflect a preference for vendors with proven capabilities in handling high-risk pathogens, maintaining BSL-3/4 containment compliance, and delivering validated research tools. Her contracting approach emphasizes long-term reliability, regulatory adherence, and scientific rigor over volume-based procurement, fostering trusted vendor relationships grounded in technical competence rather than broad competition. Her procurement portfolio reflects no set-aside preferences, with 100% of awards issued under unrestricted competition. This indicates a prioritization of technical capability and mission-critical performance over socioeconomic categorizations, consistent with NIAID’s emphasis on scientific urgency and specialized expertise in high-consequence research domains. Esters’ acquisitions are exclusively classified under NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—underscoring her deep specialization in life sciences R&D. She procures services including pathogen characterization, assay development, biosafety training, and laboratory system integration, requiring contractors with advanced capabilities in virology, immunology, and biocontainment engineering. Her work supports the agency’s core function of translating scientific discovery into operational readiness for emerging health threats.